Business
Sierra Oncology to Present at ASCO Annual Meeting
Sierra Oncology to Present at ASCO Annual Meeting.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 1423G Sareum Holdings PLC 25 May 2017 \n\n\n\n\n\n(AIM: SAR)\n\n\n25 May 2016\n\n\n\n\nSAREUM HOLDINGS PLC\n(\"Sareum\" or \"the Company\")\nSierra Oncology to Present Chk1 Clinical Trial Enhancements\nat ASCO Annual Meeting \nSareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, notes an announcement made by Sierra Oncology, Inc. yesterday stating that it will be presenting two Trials in Progress posters describing the innovative Phase 1 clinical designs for its Chk1 inhibitor, SRA737, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago on June 5th.\nThese ongoing trials were recently amended to include cohort expansions of prospectively selected patients with tumors identified to have genetic abnormalities that are thought to confer sensitivity to Chk1 therapy.\nThe full announcement can be found on Sierra Oncology's IR website*.\nDr Tim Mitchell, CEO of Sareum, commented: \"This announcement shows the interest by the scientific community in Sierra's leading-edge strategy that builds on Chk1's specific biological role in cancer, which has been made possible by recent developments in genetic analysis and is part of the progress towards personalised anti-cancer therapies. We look forward to keeping investors abreast of Sierra's progress and we can expect a further update from Sierra in early 2018.\"\nSierra Oncology holds exclusive and worldwide rights for the Chk1 inhibitor, SRA737, having licensed the programme from Sareum's co-investment partner, the CRT Pioneer Fund in September 2016. This announcement does not trigger any milestone payments under the terms of the agreement.\n*http://investor.sierraoncology.com/2017-05-24-Sierra-Oncology-to-Present-Innovative-Clinical-Trial-Enhancements-Leveraging-Chk1-Synthetic-Lethality-in-Two-Posters-at-ASCO-Annual-Meeting\nFor further information, please contact: \n\n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nWH Ireland Limited (Nominated Adviser and Co-Broker)\n\n\n\n\nChris Fielding / Nick Prowting\n\n\n020 7220 1666\n\n\n\n\nHybridan LLP (Co-Broker)\n\n\n \n\n\n\n\nClaire Noyce\n\n\n020 3764 2341\n\n\n\n\nThe Communications Portfolio (Sareum Media enquiries)\n\n\n \n\n\n\n\nAriane Comstive\nAriane.comstive@communications-portf...